David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Dissertation, Salve Regina University (1999)
The purpose of this study is to analyze the problematic impact of technology on American health care. Although the pharmaceutical industry's use of technology has produced beneficial results, at times the industry seems to overlook the unintended consequences involved. This study also examines the pharmaceutical industry's attempts to influence the physician's prescribing decisions as well as the patient's desire to get well as soon as possible. It analyzes the FDA's role in approving drugs, in monitoring the post-approval process, and in overseeing the industry's technological excesses. While the industry has the admirable goal of trying to relieve or eradicate illness, a few firms regularly engage in questionable behavior as they strive to increase their profitability. In addition to using ethically suspect marketing techniques, some firms suppress unfavorable research. In sum, it is clear that the drug industry needs to engage in deeper ethical reflection
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1):41-51.
Joao Calinas-Correia (2013). Big Pharma: A Story of Success in a Market Economy. [REVIEW] Medicine, Health Care and Philosophy 16 (2):305-309.
Denis Gordon Arnold (ed.) (2009). Ethics and the Business of Biomedicine. Cambridge University Press.
David Badcott (2013). Big Pharma: A Former Insider's View. [REVIEW] Medicine, Health Care and Philosophy 16 (2):249-264.
Edward R. Balotsky (2009). Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries. [REVIEW] Journal of Business Ethics 84 (1):75 - 88.
Marc A. Rodwin (2011). Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan. Journal of Law, Medicine & Ethics 39 (4):662-670.
Ya-Hui Hsu, Wenchang Fang & Yuanchung Lee (2009). Ethically Questionable Behavior in Sales Representatives — An Example From the Taiwanese Pharmaceutical Industry. Journal of Business Ethics 88 (1):155 - 166.
Jay P. Mulki, Jorge Fernando Jaramillo & William B. Locander (2009). Critical Role of Leadership on Ethical Climate and Salesperson Behaviors. Journal of Business Ethics 86 (2):125 - 141.
Steven C. Schachter (ed.) (2008). Managing Relationships with Industry: A Physician's Compliance Manual. Elsevier.
Sue Eckstein (ed.) (2003). Manual for Research Ethics Committees. Cambridge University Press.
Added to index2012-02-23
Total downloads7 ( #264,410 of 1,696,633 )
Recent downloads (6 months)2 ( #250,163 of 1,696,633 )
How can I increase my downloads?